Market Overview

Has Celgene Become Vulnerable To 'Revenue Concentration Risk'?

Share:
Has Celgene Become Vulnerable To 'Revenue Concentration Risk'?

Argus' David Toung downgraded shares of Celgene Corporation (NASDAQ: CELG) from Buy to Hold after fully digesting the company's first-quarter earnings report.

Stay Critical, Investors

According to Toung, investors have reason to be "concerned" over the company's revenue concentration from Revlimid, a treatment for multiple myeloma and other conditions. During the recent quarter, sales of Revlimid accounted for 64 percent of total revenue and that proportion is only growing.

Toung also noted Celgene's steep discounting of Otezla, a treatment for plaque psoriasis and psoriatic arthritis, could pressure margins moving forward. The company cited a strategy of lowering the price to boost sales among large institutions and could be a strategy of being placed ahead of biologic drugs as a treatment, which may prove successful but definitely requires close monitoring moving forward.

On the positive side, the analyst is encouraged by Celgene's "formidable" new drug pipeline along with new indications for existing drugs.

Finally, Toung pointed out that shares of Celgene have risen a "strong" 23 percent over the past year and are now trading at a valuation of 14.9x his 2018 earnings per share estimate. This multiple represents a premium above other pharmaceutical stocks that the analyst covers at 13.4x.

Related Links:

Leerink Presents: Your 2017 Biopharma Catalyst Tracker

Couldn't Make It To Leerink's Global Healthcare Conference? Here Are The Highlights From Day One

Latest Ratings for CELG

DateFirmActionFromTo
Nov 2019DowngradesBuyHold
Nov 2019DowngradesOutperformNeutral
May 2019DowngradesOverweightEqual-Weight

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Earnings News Guidance Downgrades Health Care Analyst Ratings Best of Benzinga

 

Related Articles (CELG)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com